• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环 miRNA 作为多发性骨髓瘤和意义未明的单克隆丙种球蛋白血症的诊断生物标志物。

Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.

机构信息

Medical School of Chinese PLA & Medical Laboratory Center, The First Medical Center of Chinese PLA General Hospital, Beijing, China.

Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

出版信息

J Clin Lab Anal. 2020 Jun;34(6):e23233. doi: 10.1002/jcla.23233. Epub 2020 Feb 10.

DOI:10.1002/jcla.23233
PMID:32039495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7307343/
Abstract

BACKGROUND

Multiple myeloma (MM) is still an incurable hematological malignancy evolved from asymptomatic monoclonal gammopathy of undetermined significance (MGUS). New evidence suggests that circulating microRNAs (miRNAs) can serve as stable diagnostic biomarkers for MM and MUGS.

METHODS

Serum miRNAs in MM patients, MUGS patients, and healthy controls (HC) were performed by Agilent Bioanalyzer 2100. MicroRNAs in MM detected as promising biomarkers were validated by using quantitative real-time PCR (qRT-PCR). Receiver operator characteristic (ROC) curve and multivariate logistic analysis were used to evaluate the diagnostic value of miRNAs for MM and MUGS.

RESULTS

In microarray analysis, the top ten differential expressed miRNAs in MM included miR-134-5p, miR-107, miR-15a-5p, miR-5159-3p, miR-1914-3p, miR-4723-3p, miR-5588-3p, miR-6893-3p, miR-7106-3p, and miR-6722-5p. Three up-regulated miRNAs (miR-134-5p, miR-107, and miR-15a-5p) were further validated. The elevated expression levels of miR-134-5p, miR-107, and miR-15a-5p in qRT-PCR were increased consistent with microarray analysis. These miRNAs distinguished MM and MUGS from HC significantly. Multivariate logistic analysis showed combination miR-107, miR-15a-5p with Hb, the AUC was 0.954 (95% CI: 0.890-1.000), sensitivity of 91.3%, and specificity of 93.7% for distinguishing MM from MUGS.

CONCLUSIONS

These data demonstrate that miR-134-5p, miR-107, and miR-15a-5p are potential diagnostic biomarkers in MM and MUGS. Moreover, the combination miR-107 and miR-15a-5p with Hb can distinguish MM from MUGS.

摘要

背景

多发性骨髓瘤(MM)仍然是一种无法治愈的血液恶性肿瘤,由无症状的单克隆丙种球蛋白血症(MGUS)演变而来。新的证据表明,循环 microRNAs(miRNAs)可以作为 MM 和 MUGS 的稳定诊断生物标志物。

方法

使用 Agilent Bioanalyzer 2100 对 MM 患者、MUGS 患者和健康对照(HC)的血清 miRNAs 进行分析。通过定量实时 PCR(qRT-PCR)验证作为有前途的 MM 和 MUGS 诊断生物标志物的 miRNAs。使用接收器操作特性(ROC)曲线和多变量逻辑分析评估 miRNAs 对 MM 和 MUGS 的诊断价值。

结果

在微阵列分析中,MM 中差异表达的前 10 个 miRNA 包括 miR-134-5p、miR-107、miR-15a-5p、miR-5159-3p、miR-1914-3p、miR-4723-3p、miR-5588-3p、miR-6893-3p、miR-7106-3p 和 miR-6722-5p。进一步验证了三个上调的 miRNA(miR-134-5p、miR-107 和 miR-15a-5p)。qRT-PCR 中 miR-134-5p、miR-107 和 miR-15a-5p 的表达水平升高与微阵列分析一致。这些 miRNA 可以显著区分 MM 和 MUGS 与 HC。多变量逻辑分析显示,miR-107、miR-15a-5p 与 Hb 联合,AUC 为 0.954(95%CI:0.890-1.000),对区分 MM 与 MUGS 的灵敏度为 91.3%,特异性为 93.7%。

结论

这些数据表明,miR-134-5p、miR-107 和 miR-15a-5p 是 MM 和 MUGS 的潜在诊断生物标志物。此外,miR-107 和 miR-15a-5p 与 Hb 的联合可以区分 MM 与 MUGS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/9fd8dfaaf98a/JCLA-34-e23233-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/2244afc4eacb/JCLA-34-e23233-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/26a3aef9325e/JCLA-34-e23233-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/0ddef7682300/JCLA-34-e23233-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/9fd8dfaaf98a/JCLA-34-e23233-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/2244afc4eacb/JCLA-34-e23233-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/26a3aef9325e/JCLA-34-e23233-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/0ddef7682300/JCLA-34-e23233-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4452/7307343/9fd8dfaaf98a/JCLA-34-e23233-g004.jpg

相似文献

1
Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.循环 miRNA 作为多发性骨髓瘤和意义未明的单克隆丙种球蛋白血症的诊断生物标志物。
J Clin Lab Anal. 2020 Jun;34(6):e23233. doi: 10.1002/jcla.23233. Epub 2020 Feb 10.
2
Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.循环血清微小RNA作为多发性骨髓瘤和意义未明的单克隆丙种球蛋白病的新型诊断和预后生物标志物。
Haematologica. 2014 Mar;99(3):511-8. doi: 10.3324/haematol.2013.093500. Epub 2013 Nov 15.
3
MicroRNAs in urine as diagnostic biomarkers for multiple myeloma.尿液中的 microRNAs 作为多发性骨髓瘤的诊断生物标志物。
Int J Lab Hematol. 2021 Apr;43(2):227-234. doi: 10.1111/ijlh.13367. Epub 2020 Oct 17.
4
Identification of plasma miR-4505, miR-4743-5p and miR-4750-3p as novel diagnostic biomarkers for coronary artery disease in patients with type 2 diabetes mellitus: a case-control study.鉴定血浆 miR-4505、miR-4743-5p 和 miR-4750-3p 作为 2 型糖尿病患者冠心病的新型诊断生物标志物:病例对照研究。
Cardiovasc Diabetol. 2024 Jul 29;23(1):278. doi: 10.1186/s12933-024-02374-0.
5
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma.鉴定循环 microRNAs 作为多发性骨髓瘤的诊断生物标志物。
Br J Cancer. 2012 Dec 4;107(12):1987-96. doi: 10.1038/bjc.2012.525. Epub 2012 Nov 20.
6
Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves' disease.循环 microRNA-144-3p 和 miR-762 是 Graves 病的新型生物标志物。
Endocrine. 2019 Jul;65(1):102-109. doi: 10.1007/s12020-019-01884-2. Epub 2019 Apr 4.
7
Circulating MicroRNAs as Potential Molecular Biomarkers for Intracranial Aneurysmal Rupture.循环 microRNAs 作为颅内动脉瘤破裂的潜在分子生物标志物。
Mol Diagn Ther. 2020 Jun;24(3):351-364. doi: 10.1007/s40291-020-00465-8.
8
Circulating miRNA in functional tricuspid regurgitation. Unveiling novel links to heart failure: A pilot study.功能性三尖瓣反流中的循环 miRNA:揭示与心力衰竭的新关联:一项初步研究。
ESC Heart Fail. 2024 Aug;11(4):2272-2286. doi: 10.1002/ehf2.14765. Epub 2024 Apr 18.
9
Circulating microRNAs as biomarkers for Sepsis secondary to pneumonia diagnosed via Sepsis 3.0.循环 microRNAs 作为通过 Sepsis 3.0 诊断的肺炎继发脓毒症的生物标志物。
BMC Pulm Med. 2019 May 14;19(1):93. doi: 10.1186/s12890-019-0836-4.
10
Circulating miR-3197 and miR-2116-5p as novel biomarkers for diabetic retinopathy.循环 miR-3197 和 miR-2116-5p 作为糖尿病视网膜病变的新型生物标志物。
Clin Chim Acta. 2020 Feb;501:147-153. doi: 10.1016/j.cca.2019.10.036. Epub 2019 Oct 31.

引用本文的文献

1
Altered miRNA expression in the lesions of cutaneous leishmaniasis caused by L. major and L. tropica with insights into apoptosis regulation.硕大利什曼原虫和热带利什曼原虫引起的皮肤利什曼病病变中miRNA表达的改变及其对细胞凋亡调控的见解
Sci Rep. 2025 Jul 1;15(1):20680. doi: 10.1038/s41598-025-03802-1.
2
A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma.硼替佐米耐药多发性骨髓瘤中循环miRNA生物标志物的预后、诊断和治疗的主题分析
SAGE Open Med. 2025 Apr 26;13:20503121251328486. doi: 10.1177/20503121251328486. eCollection 2025.
3
Mitochondria-associated programmed cell death: elucidating prognostic biomarkers, immune checkpoints, and therapeutic avenues in multiple myeloma.

本文引用的文献

1
Prognostic relevance of telomere length and telomerase reverse transcriptase variant (rs2242652) on the multiple myeloma patients.端粒长度和端粒酶逆转录酶变体(rs2242652)对多发性骨髓瘤患者的预后相关性。
J Clin Lab Anal. 2020 Apr;34(4):e23133. doi: 10.1002/jcla.23133. Epub 2019 Dec 8.
2
Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis.新诊断需要血液透析的多发性骨髓瘤患者血液透析独立性高的相关影响因素。
J Clin Lab Anal. 2020 Feb;34(2):e23057. doi: 10.1002/jcla.23057. Epub 2019 Oct 30.
3
Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.
线粒体相关的程序性细胞死亡:阐明多发性骨髓瘤中的预后生物标志物、免疫检查点和治疗途径
Front Immunol. 2024 Dec 11;15:1448764. doi: 10.3389/fimmu.2024.1448764. eCollection 2024.
4
Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma.非编码RNA在多发性骨髓瘤诊断、预测及预后中的作用
Cancers (Basel). 2024 Mar 2;16(5):1033. doi: 10.3390/cancers16051033.
5
mA-Mediated Upregulation of lncRNA CHASERR Promotes the Progression of Glioma by Modulating the miR-6893-3p/TRIM14 Axis.mA 介导的长链非编码 RNA CHASERR 的上调通过调节 miR-6893-3p/TRIM14 轴促进胶质瘤的进展。
Mol Neurobiol. 2024 Aug;61(8):5418-5440. doi: 10.1007/s12035-023-03911-w. Epub 2024 Jan 9.
6
Identifying the potential genes in alpha synuclein driving ferroptosis of Parkinson's disease.鉴定α-突触核蛋白中导致帕金森病铁死亡的潜在基因。
Sci Rep. 2023 Oct 6;13(1):16893. doi: 10.1038/s41598-023-44124-4.
7
The role of microRNA-4723-5p regulated by c-myc in triple-negative breast cancer.c-myc 调控的 microRNA-4723-5p 在三阴性乳腺癌中的作用。
Bioengineered. 2022 Apr;13(4):9097-9105. doi: 10.1080/21655979.2022.2056824.
8
MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease.微小RNA作为从无症状多发性骨髓瘤向有症状多发性骨髓瘤转变的一种潜在新预防方法。
Cancers (Basel). 2021 Jul 21;13(15):3650. doi: 10.3390/cancers13153650.
9
Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations.循环微小RNA作为多发性骨髓瘤的辅助诊断生物标志物:系统评价、荟萃分析及建议
Front Oncol. 2021 Jul 8;11:698197. doi: 10.3389/fonc.2021.698197. eCollection 2021.
10
Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis.循环微小RNA对多发性骨髓瘤的潜在诊断价值:一项荟萃分析。
J Bone Oncol. 2020 Oct 21;25:100327. doi: 10.1016/j.jbo.2020.100327. eCollection 2020 Dec.
肾功能受损的老年多发性骨髓瘤患者的临床特征和治疗结果。
J Clin Lab Anal. 2019 Jun;33(5):e22888. doi: 10.1002/jcla.22888. Epub 2019 Apr 19.
4
DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.骨髓增生异常综合征和急性髓细胞白血病患者间充质干细胞中的DICER1基因与微小RNA失调
Leuk Res. 2017 Dec;63:62-71. doi: 10.1016/j.leukres.2017.10.006. Epub 2017 Oct 31.
5
MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma.微小RNA-15a/16通过抑制多发性骨髓瘤中Bcl-2、血管内皮生长因子-A和白细胞介素-17的表达来调节骨髓瘤细胞的生长、血管生成和抗肿瘤免疫。
Leuk Res. 2016 Oct;49:73-9. doi: 10.1016/j.leukres.2016.08.013. Epub 2016 Aug 28.
6
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.多发性骨髓瘤,2016年第2版:肿瘤学临床实践指南
J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435. doi: 10.6004/jnccn.2015.0167.
7
MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.位于染色体13q14的微小RNA-15a/16-1簇在多发性骨髓瘤中表达下调,但呈现出不同的表达模式和预后意义。
Oncotarget. 2015 Nov 10;6(35):38270-82. doi: 10.18632/oncotarget.5681.
8
Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.骨髓瘤患者骨髓微环境和外周血中miRNA水平异常与疾病进展
J Mol Diagn. 2015 Nov;17(6):669-78. doi: 10.1016/j.jmoldx.2015.06.006. Epub 2015 Sep 30.
9
Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma.多环芳烃对靶向p53的微小RNA的调控:对多发性骨髓瘤病因学的影响。
Mol Carcinog. 2015 Oct;54(10):1060-9. doi: 10.1002/mc.22175. Epub 2014 May 6.
10
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma.鉴定循环 microRNAs 作为多发性骨髓瘤的诊断生物标志物。
Br J Cancer. 2012 Dec 4;107(12):1987-96. doi: 10.1038/bjc.2012.525. Epub 2012 Nov 20.